ArticleBriefings in bioinformatics2026
BOMIFA: biologically informed multi-omics integration with graph contrastive learning for cancer prognosis in women.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Accurate survival prediction remains a central challenge in precision oncology, particularly for female patients whose sex-specific molecular characteristics are often under-modeled in prior studies. Although multi-omics integration enables a deeper exploration of prognostic biomarkers, existing methods rely on mathematically driven fusion strategies, which tend to dilute omics-specific signals and fail to capture biological regulatory hierarchies across omics layers. To address these limitations, we propose BOMIFA (Biologically informed Omics representation and Multi-omics Integration Framework), a deep graph-based framework for survival prediction and biomarker discovery in female patients using DNA methylation, mRNA, and miRNA expression data. BOMIFA incorporates two key innovations. First, graph contrastive learning is leveraged within each omics encoder to enhance intra-omics representation learning and amplify prognostically relevant signals. Then, a biologically informed cross-omics attention mechanism is deployed to explicitly model directional regulatory dependencies, enabling inter-omics information exchange aligned with known molecular hierarchies. Extensive benchmarking on eight cancer cohorts demonstrates that BOMIFA consistently outperforms existing prognostic methods in female patients. Moreover, saliency map-based gradient attribution enables the identification of female-associated prognostic biomarkers that were overlooked in prior mixed-sex analyses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.